Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
aquaphilus dolomiae extract
- Development stage
- Unknown
- Lead developer
- Pierre Fabre Dermo-Cosmétique
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics
- Administration
- Topical
01
Overview
Aquaphilus dolomiae extract is a postbiotic biotechnological extract derived from a unique non-pathogenic, Gram-negative bacterium found in Avène Thermal Spring Water. Developed by Pierre Fabre, this extract is a key active ingredient in dermocosmetic formulations (such as the Avène XeraCalm A.D and Cicalfate+ lines) designed to treat inflammatory skin conditions. It exhibits a multi-pronged mechanism of action: it improves skin barrier function by restoring filaggrin expression and strengthening tight junctions; it modulates neurogenic inflammation by inhibiting the release of substance P and pro-inflammatory cytokines like IL-1β, TNF-α, and IL-8; and it enhances innate immunity by acting as an agonist for Toll-like receptors (TLR2, TLR4, and TLR5), which induces the production of antimicrobial peptides. Clinical studies have demonstrated its effectiveness in reducing pruritus, xerosis, and inflammation in patients with atopic dermatitis and sensitive skin.
- Brand names
- I-moduliaC+ Restore
- Other names
- Aquaphilus dolomiae extract-G1Aquaphilus dolomiae extract-G2Aquaphilus dolomiae extract-G3Aquaphilus dolomiae fermentation extract
02
Targets
TLR2 (Toll-like Receptor 2)TLR4 (Toll-like receptor 4)TLR5PAR2 (Protease-activated receptor 2)
Beyond the preview
Go deeper on aquaphilus dolomiae extract.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on aquaphilus dolomiae extract.